Characteristics | Unadjusted OR (95% CI) | Model I | Model II | Model III | |||
---|---|---|---|---|---|---|---|
Adjusted OR (95% CI) | Attributable risk | Adjusted OR (95% CI) | Attributable risk | Adjusted OR (95% CI) | Attributable risk | ||
Age ≥ 70 | 1.00 (0.56–1.78) | ||||||
Diabetes mellitus | 1.78 (1.00–3.16)* | ||||||
Duration ≥12 weeks | 2.55 (1.43–4.55)** | 2.00 (1.03–3.88)* | 49.9 | 1.98 (1.06–3.71)* | 49.5 | 2.03 (1.10–3.72)* | 50.6 |
GABA analogue | 3.85 (2.01–7.37)*** | 2.14 (0.97–4.75) | 3.92 (2.00–7.67)*** | 74.5 | 2.67 (1.35–5.30)** | 62.5 | |
Oxycodonea | 5.25 (1.73–15.91)** | 3.75 (1.20–11.72)* | 73.3 | ||||
Morphinea | 8.84 (2.89–26.99)*** | 5.31 (1.60–17.59)** | 81.2 | ||||
Combination therapy | 2.51 (1.14–5.52)* | 2.33 (0.96–5.64) | |||||
MME ≥ 60 | 5.58 (2.31–13.46)*** | 3.38 (1.34–8.52)* | 70.4 |